PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); ...
Q2 2026
Aug 27, 2026
Q1 2026
Apr 29, 2026
FY 2025
Q2 2025
Aug 28, 2025
Q1 2025
Apr 30, 2025